The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Glycemic Goals in Diabetes: Trade-off Between Glycemic Control and Iatrogenic Hypoglycemia
Open accessAbstract
The selection of a glycemic goal in a person with diabetes is a compromise between the documented upside of glycemic control—the partial prevention or delay of microvascular complications—and the documented downside of glycemic control—the recurrent morbidity and potential mortality of iatrogenic hypoglycemia. The latter is not an issue if glycemic control is accomplished with drugs that do not cause hypoglycemia or with substantial weight loss. However, hypoglycemia becomes an issue if glycemic control is accomplished with a sulfonylurea, a glinide, or insulin, particularly in the setting of absolute endogenous insulin deficiency with loss of the normal decrease in circulating insulin and increase in glucagon secretion and attenuation of the sympathoadrenal response as plasma glucose concentrations fall. Then the selection of a glycemic goal should be linked to the risk of hypoglycemia. A reasonable individualized glycemic goal is the lowest A1C that does not cause severe hypoglycemia and preserves awareness of hypoglycemia, preferably with little or no symptomatic or even asymptomatic hypoglycemia, at a given stage in the evolution of the individual’s diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Intensive versus Conventional Glucose Control in Critically Ill Patients
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810625 · Cited by 5,119
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Cited by
Chatterjee, S., Khunti, K., & Davies, M. J. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30058-2 · Cited by 2,577
Grundy, S. M. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.10.004 · Cited by 882
Hering, B. J., Clarke, W. R., Bridges, N. D., Eggerman, T. L., Alejandro, R., Bellin, M. D., Chaloner, K., Czarniecki, C. W., Goldstein, J. S., Hunsicker, L. G., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1988 · Cited by 645
Diabetic emergencies - ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia
Umpierrez, G., & Korytkowski, M. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.15 · Cited by 563
Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes
Monnier, L., Colette, C., Wojtusciszyn, A., Dejager, S., Renard, E., Molinari, N., & Owens, D. R. (2017) · Diabetes Care · doi:10.2337/dc16-1769 · Cited by 390
Islet α cells and glucagon--critical regulators of energy homeostasis
Campbell, J. E., & Drucker, D. J. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.51 · Cited by 266
Metrics for glycaemic control - from HbA1c to continuous glucose monitoring
Kovatchev, B. P. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.3 · Cited by 272
The somatostatin-secreting pancreatic δ-cell in health and disease
Rorsman, P., & Huising, M. O. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0020-6 · Cited by 259
Glucose Variability: Timing, Risk Analysis, and Relationship to Hypoglycemia in Diabetes
Kovatchev, B., & Cobelli, C. (2016) · Diabetes Care · doi:10.2337/dc15-2035 · Cited by 255
Choudhary, P., Rickels, M. R., Senior, P. A., Vantyghem, M.-C., Maffi, P., Kay, T. W., Keymeulen, B., Inagaki, N., Saudek, F., Lehmann, R., et al. (2015) · Diabetes Care · doi:10.2337/dc15-0090 · Cited by 233
Marfil-Garza, B. A., Imes, S., Verhoeff, K., Hefler, J., Lam, A., Dajani, K., Anderson, B., O'Gorman, D., Kin, T., Bigam, D., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00114-0 · Cited by 205
Positioning time in range in diabetes management
Advani, A. (2020) · Diabetologia · doi:10.1007/s00125-019-05027-0 · Cited by 170
Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion
Vergari, E., Knudsen, J. G., Ramracheya, R., Salehi, A., Zhang, Q., Adam, J., Asterholm, I. W., Benrick, A., Briant, L. J. B., Chibalina, M. V., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08193-8 · Cited by 152
Glycemic variability: how to measure and its clinical implication for type 2 diabetes
Umpierrez, G. E., & P. Kovatchev, B. (2018) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2018.09.010 · Cited by 148
Bergenstal, R. M. (2015) · Diabetes Care · doi:10.2337/dc15-0099 · Cited by 140
Novodvorsky, P., Bernjak, A., Chow, E., Iqbal, A., Sellors, L., Williams, S., Fawdry, R. A., Parekh, B., Jacques, R. M., Marques, J. L. B., et al. (2017) · Diabetes Care · doi:10.2337/dc16-2177 · Cited by 111
Haynes, A., Hermann, J. M., Miller, K. M., Hofer, S. E., Jones, T. W., Beck, R. W., Maahs, D. M., Davis, E. A., Holl, R. W., & for the T1D Exchange, W. A. D. R. (2017) · Pediatric Diabetes · doi:10.1111/pedi.12477 · Cited by 88
“is how to achieve optimal glycemic control, without increasing the risk of severe hypoglycemia.(1) The landmark Diabetes Control and Complications Trial (DCCT) reported a significantly reduced risk of”
BackgroundA Century of Diabetes Technology: Signals, Models, and Artificial Pancreas Control
Kovatchev, B. (2019) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.04.008 · Cited by 80
Randomized Controlled Trial of Mobile Closed-Loop Control
Kovatchev, B., Anderson, S. M., Raghinaru, D., Kudva, Y. C., Laffel, L. M., Levy, C., Pinsker, J. E., Wadwa, R. P., Buckingham, B., Doyle, F. J., et al. (2020) · Diabetes Care · doi:10.2337/dc19-1310 · Cited by 60
Hood, R. C., Arakaki, R. F., Wysham, C., Li, Y. G., Settles, J. A., & Jackson, J. A. (2015) · Endocrine Practice · doi:10.4158/ep15612.or · Cited by 61
Hill, T. G., Gao, R., Benrick, A., Kothegala, L., Rorsman, N., Santos, C., Acreman, S., Briant, L. J., Dou, H., Gandasi, N. R., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01139-z · Cited by 37
“5b), indicates the existence of stimulatory mechanisms in addition to urocortin-3.”
Hirsch, I. B., & Verderese, C. A. (2017) · Endocrine Practice · doi:10.4158/ep171962.ra · Cited by 22
Pedersen‐Bjergaard, U., Agesen, R. M., Brøsen, J. M. B., Alibegovic, A. C., Andersen, H. U., Beck‐Nielsen, H., Gustenhoff, P., Hansen, T. K., Hedetoft, C., Jensen, T. J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14574 · Cited by 16
Zaccardi, F., Webb, D. R., Davies, M. J., Dhalwani, N. N., Housley, G., Shaw, D., Hatton, J. W., & Khunti, K. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12941 · Cited by 15
The Italian Society of Emergency Medicine (SIMEU), Veronese, G., Marchesini, G., Forlani, G., & Fabbri, A. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0844-2 · Cited by 7
Metadata
- Authors
- Cryer, P. E.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-06-14
- Volume
- 63
- Issue
- 7
- Pages
- 2188-2195
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2132141620
- Cited by
- 236
- References
- 39
- FWCI
- 14.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.